Grading allergic ocular disease

Article

Research published online ahead of print by Graefe's Archive for Clinical and Experimental Ophthalmology, has revealed that allergic ocular diseases can be classified and clinically evaluated using a grading system.

Research published online ahead of print by Graefe's Archive for Clinical and Experimental Ophthalmology, has revealed that allergic ocular diseases can be classified and clinically evaluated using a grading system.

Eiichi Uchio and colleagues from Fukuoka University School of Medicine, Japan created a number of criteria for classifying and clinically evaluating the severity of allergic ocular diseases. They then evaluated the effectiveness of the criteria in the diagnosis of 1,079 patients.

The researchers diagnosed and classified allergic conjunctivitis, atopic keratoconjunctivitis and vernal keratoconjunctivitis based on local and systemic clinical findings. Ten objective conjunctival, limbal and corneal lesion findings were graded on a four-point scale. The total score was used as the clinical score, with a highest value of 30.

Of the 1,079 subjects, 876 (81.2%) were diagnosed with seasonal allergic conjunctivitis, 115 (10.7%) with perennial allergic conjunctivitis, 47 (4.4%) with atopic keratoconjunctivitis and 41 (3.8%) with vernal keratoconjunctivitis. The total clinical scores were 1.54 in seasonal allergic conjunctivitis, 2.13 in perennial allergic conjunctivitis, 3.72 in atopic keratoconjunctivitis and 12.68 in vernal keratoconjunctivitis.

The authors concluded that re-evaluation of allergic ocular disease is necessary for building future strategies for its treatment.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.